Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Rating) Director Robert W. Postma bought 750,000 shares of the business's stock in a transaction on Tuesday, November 29th. The shares were acquired at an average cost of $0.65 per share, for a total transaction of $487,500.00. Following the transaction, the director now directly owns 5,000,000 shares in the company, valued at approximately $3,250,000. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.
Alaunos Therapeutics Stock Performance
TCRT stock opened at $0.64 on Friday. The firm has a 50 day moving average of $1.25 and a 200 day moving average of $1.41. Alaunos Therapeutics, Inc. has a 52 week low of $0.41 and a 52 week high of $4.01.
Get Alaunos Therapeutics alerts:Wall Street Analyst Weigh In
Separately, Wells Fargo & Company reaffirmed an "overweight" rating and issued a $3.00 price objective on shares of Alaunos Therapeutics in a research report on Tuesday, October 4th.
Institutional Trading of Alaunos Therapeutics
A number of institutional investors have recently bought and sold shares of the stock. E Fund Management Co. Ltd. acquired a new stake in Alaunos Therapeutics in the 3rd quarter worth approximately $26,000. SevenBridge Financial Group LLC acquired a new stake in Alaunos Therapeutics in the 3rd quarter worth approximately $34,000. UBS Group AG boosted its stake in Alaunos Therapeutics by 7.6% in the 3rd quarter. UBS Group AG now owns 288,597 shares of the company's stock worth $496,000 after purchasing an additional 20,422 shares in the last quarter. Nicolet Advisory Services LLC acquired a new stake in Alaunos Therapeutics in the 2nd quarter worth approximately $30,000. Finally, BNP Paribas Arbitrage SNC boosted its stake in Alaunos Therapeutics by 67.5% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 58,847 shares of the company's stock worth $101,000 after purchasing an additional 23,704 shares in the last quarter. 33.88% of the stock is currently owned by institutional investors and hedge funds.About Alaunos Therapeutics
(Get Rating)
Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors.
Featured Articles
- Get a free copy of the StockNews.com research report on Alaunos Therapeutics (TCRT)
- Ford Revving Up Production Of EV Power Units At U.K. Plant
- Are the Short Sellers Still Right About Mullen Automotive stock?
- La-Z-Boy Reclines To More Comfortable Levels
- Is Apple Going To Rally Into Year End?
- Is The Recovery Rally Here For SoFi?
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.